Remdesivir (RDV) has been shown to inhibit MASLD progression by ameliorating dyslipidemia and inflammatory responses, with its regulatory effects attributed, in part, to the blockade of the STING signaling pathway (109). Here, STING1 is linked to metabolic dysfunction-associated steatotic liver disease.